`
`News
`Select
`
`Mylan Completes Acquisition of Meda Aug 5, 2016
`
`Mylan Completes Acquisition of Meda
`
`HERTFORDSHIRE, England and PITTSBURGH, Aug. 5, 2016 /PRNewswire/ Mylan N.V. (NASDAQ,
`TASE: MYL) today announced that it has completed the settlement of its recommended public offer to
`the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the "Offer"). As
`previously announced, the Offer was accepted by shareholders holding approximately 94% of the total
`number of outstanding shares and votes in Meda, as of July 29, 2016. Upon the completion and
`settlement of the Offer, Mylan acquired each of these shares in accordance with the terms of the Offer.
`The Offer was initially announced on Feb. 10, 2016 and it was declared unconditional on Aug. 2, 2016.
`The acceptance period expired on July 29, 2016 and will not be extended.
`
`Mylan Chairman Robert Coury commented, "We are very
`pleased to have received the overwhelming shareholder
`support required to complete our acquisition of Meda. Mylan
`continues to differentiate itself among the world's
`pharmaceutical companies in terms of our unique profile and
`growth trajectory. The addition of Meda will only further add
`to our existing leadership position within our space and
`continue to create significant value for our shareholders and other stakeholders. On behalf of Mylan's
`entire board of directors, we welcome our new Mylan shareholders and look forward to them sharing in
`the anticipated future success of our combined company."
`
`Mylan CEO Heather Bresch continued, "The addition of Meda builds on everything we have put in place
`around the world, creating even greater scale, breadth and diversity across products, geographies and
`sales channels. As a result, our R&D and manufacturing platform is unmatched, and we now have a
`more powerful global commercial infrastructure across developed and emerging markets and branded,
`generic and overthecounter products. This transaction also is extremely compelling financially,
`providing significant accretion to Mylan's adjusted earnings per share, the opportunity for substantial
`synergies and further acceleration of our growth. Importantly, I would like to welcome Meda's talented
`and dedicated workforce to the Mylan family, and I look forward to their contributions as we strive to
`deliver better health for a better world."
`
`Mylan President Rajiv Malik added, "With the addition of Meda, Mylan now has six $1 billion therapeutic
`franchises, and through our enhanced scale and expanded commercial capabilities, we see significant
`opportunities to further distinguish Mylan among our customers and patients. Allergy/respiratory,
`pain/CNS and dermatology – recently bolstered by our acquisition of the Renaissance topicals business
`– represent just a few of the exciting areas where we expect to create additional value from our
`combined portfolio, pipeline and capabilities. Meda also opens up a number of new opportunities for us,
`such as significantly expanding our overthecounter presence into a $1 billion business. Additionally,
`Meda accelerates our expansion in attractive emerging markets, such as China, Southeast Asia, Russia
`and the Middle East, and provides us opportunities to maximize our efficient, high quality operating
`platform and broad product portfolio. I too would like to extend a warm welcome to the Meda team and
`am excited to begin integrating our businesses and bringing together the best from both of our
`organizations."
`http://newsroom.mylan.com/20160805MylanCompletesAcquisitionofMeda
`
`
`1/3
`
`1
`
`CIP2100
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`
`
`5/19/2017
`
`Mylan Completes Acquisition of Meda Aug 5, 2016
`
`Meda is now a controlled subsidiary of Mylan. Mylan intends to initiate compulsory acquisition
`proceedings for the remaining shares in Meda in accordance with the Swedish Companies Act (Sw.
`aktiebolagslagen (2005:551)) and has acted to have the Meda shares delisted from Nasdaq Stockholm.
`
`Mylan discloses the information provided herein pursuant to Nasdaq Stockholm's Takeover Rules (the
`"Takeover Rules"). The information was submitted for publication on Aug. 5, 2016, 15:00 CET.
`ForwardLooking Statements
`
`This communication contains "forwardlooking statements." Such forwardlooking statements may
`include, without limitation, statements about the acquisition of Meda by Mylan (the "Meda Transaction"),
`the Offer, the benefits and synergies of the Meda Transaction, future opportunities for Mylan, Meda, or
`the combined company and products and any other statements regarding Mylan's, Meda's or the
`combined company's future operations, anticipated business levels, future earnings, planned activities,
`anticipated growth, market opportunities, strategies, competition, and other expectations and targets for
`future periods. These may often be identified by the use of words such as "will," "may," "could," "should,"
`"would," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend,"
`"continue," "target" and variations of these words or comparable words. Because forwardlooking
`statements inherently involve risks and uncertainties, actual future results may differ materially from
`those expressed or implied by such forwardlooking statements. Factors that could cause or contribute
`to such differences include, but are not limited to: uncertainties related to the Meda Transaction; the
`ability to meet expectations regarding the accounting and tax treatments of Mylan's acquisition (the
`"EPD Transaction") of Mylan Inc. and Abbott Laboratories' nonU.S. developed markets specialty and
`branded generics business (the "EPD Business") and the Meda Transaction; changes in relevant tax
`and other laws, including but not limited to changes in the U.S. tax code and healthcare and
`pharmaceutical laws and regulations in the U.S. and abroad; the integration of the EPD Business and
`Meda being more difficult, timeconsuming, or costly than expected; operating costs, customer loss, and
`business disruption (including, without limitation, difficulties in maintaining relationships with employees,
`customers, clients, or suppliers) being greater than expected following the EPD Transaction and the
`Meda Transaction; the retention of certain key employees of the EPD Business and Meda being difficult;
`the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in
`connection with the EPD Transaction and the Meda Transaction within the expected timeframes or at all
`and to successfully integrate the EPD Business and Meda; expected or targeted future financial and
`operating performance and results; the capacity to bring new products to market, including but not
`limited to where Mylan uses its business judgment and decides to manufacture, market, and/or sell
`products, directly or through third parties, notwithstanding the fact that allegations of patent
`infringement(s) have not been finally resolved by the courts (i.e., an "atrisk launch"); any regulatory,
`legal, or other impediments to Mylan's ability to bring new products to market; success of clinical trials
`and Mylan's ability to execute on new product opportunities; any changes in or difficulties with our
`inventory of, and our ability to manufacture and distribute, the EpiPen® AutoInjector to meet anticipated
`demand; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such
`proceedings on financial condition, results of operations, and/or cash flows; the ability to protect
`intellectual property and preserve intellectual property rights; the effect of any changes in customer and
`supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel;
`changes in thirdparty relationships; the impact of competition; changes in the economic and financial
`conditions of the businesses of Mylan, Meda or the combined company; the inherent challenges, risks,
`and costs in identifying, acquiring, and integrating complementary or strategic acquisitions of other
`companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond
`the control of management; and inherent uncertainties involved in the estimates and judgments used in
`the preparation of financial statements, and the providing of estimates of financial measures, in
`accordance with accounting principles generally accepted in the United States and related standards or
`on an adjusted basis. For more detailed information on the risks and uncertainties associated with
`
`http://newsroom.mylan.com/20160805MylanCompletesAcquisitionofMeda
`
`2/3
`
`2
`
`
`
`Mylan Completes Acquisition of Meda Aug 5, 2016
`5/19/2017
`Mylan's business activities, see the risks described in Mylan's Annual Report on Form 10K for the year
`ended December 31, 2015, as amended, its Quarterly Report on Form 10Q for the three months ended
`March 31, 2016 and its other filings with the SEC. These risks and uncertainties also include those risks
`and uncertainties that are discussed in the Offer Document that was published on June 16, 2016, the
`Registration Statement which was declared effective on June 16, 2016 and the EU Prospectus that was
`published on June 16, 2016. You can access Mylan's filings with the SEC through the SEC website at
`www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update
`any statements herein for revisions or changes after the date of this communication, except as required
`by law.
`Important Notice
`This communication has been published in Swedish and English. In the event of any discrepancy in
`content between the language versions, the Swedish version shall prevail.
`About Mylan
`Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working
`together around the world to provide 7 billion people access to high quality medicine, we innovate to
`satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy;
`and impact the future through passionate global leadership. We offer a growing portfolio of more than
`2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately
`50% of people being treated for HIV/AIDS in the developing world depend. We market our products in
`more than 165 countries and territories. Our global R&D and manufacturing platform includes more than
`50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every
`member of our more than 40,000strong workforce is dedicated to creating better health for a better
`world, one person at a time. Learn more at mylan.com.
`
`Logo http://photos.prnewswire.com/prnh/20140423/77793
`
`
`
`SOURCE Mylan N.V.
`
`For further information: For further information, please contact: Media: Nina Devlin, Tel. +1 (724) 514
`1968, Nina.Devlin@mylan.com; Investors: Kris King, Tel. +1 (724) 5141813, Kris.King@mylanlabs.com
`
`http://newsroom.mylan.com/20160805MylanCompletesAcquisitionofMeda
`
`3/3
`
`3
`
`